Risk of Uncomplicated Peptic Ulcer in the General Population

AstraZeneca

Status: Completed

Conditions: Peptic Ulcer [Iowa Type (107680.0010)]

Treatments: Drug: Risk of symptomatic peptic ulcer

Study type: Observational

Funder types: Industry

Identifiers

NCT01888588

D5040N00006

Details and patient eligibility

About

The analyses are conducted in a previous population-based cohort study using The Health Improvement Network database in the UK (Cai et al 2009).The aims of the post hoc analyses are:

To estimate the relative risk of uncomplicated symptomatic peptic ulcer (UPU) associated with use of low dose aspirin (ASA) and other anti-inflammatory drugs (NSAIDs, steroids) in the general population To estimate the dose-response and duration-response associated with use of these drugs To estimate the relative risk of UPU associated with naive/non-naive use of low dose ASA in the general population To evaluate the effect of proton pump inhibitors (PPI) (alone or in combination with anti-inflammatory drugs) on the occurrence of UPU in the general population To investigate the management of low dose ASA/oral antiplatelets after UPU

Full description

Risk of uncomplicated peptic ulcer in the general population

Enrollment: 4,000 patients

Sex: All

Ages: 40 to 84 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients aged 40-84 years in 1997-2005 ( see study population description)

Exclusion criteria

• Patients aged below age 40 and 85 years and above ( see study population description)

Trial design

4,000 participants in 2 patient groups

Cases

Description:

Patients with symptomatic peptic ulcer (UPU)

Treatment:

Drug: Risk of symptomatic peptic ulcer

Control group

Description:

Control group without symptomatic peptic ulcer (UPU).

Treatment:

Drug: Risk of symptomatic peptic ulcer